 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- E2307 / Eisai
Plasma phospho-tau 217 rises with and not before early tau aggregation measured by MK6240 PET (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_905;
Figure 1 legend: Modeling of 18 F-MK6240 quantification and pTau217 as a function of Centiloid. Biomarker values Z-scored using the results from A?- cognitively unimpaired to define the normal range for p217+tau level and each tau PET ROI SUVR.
- E2307 / Eisai
Plasma phospho-tau 217 rises with and not before early tau aggregation measured by MK6240 PET ((Pennsylvania Convention Center)) - Jun 19, 2024 - Abstract #AAIC2024AAIC_248;
2022 Apr 5;14(1):e12307. This data suggests that the amygdala is a robust region for detecting early tau aggregation by MK6240 PET and that a rise in plasma pTau217 is associated with early formation of NFT rather than a direct physiological response to brain A
- | E2307 / Eisai
Trial completion: A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects (clinicaltrials.gov) - Jan 19, 2016
P1, N=24, Completed, Sponsor: Eisai Co., Ltd.
This data suggests that the amygdala is a robust region for detecting early tau aggregation by MK6240 PET and that a rise in plasma pTau217 is associated with early formation of NFT rather than a direct physiological response to brain A Active, not recruiting --> Completed
- E2307 / Eisai
Enrollment closed, Enrollment change: A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects (clinicaltrials.gov) - Jun 6, 2015
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=64 --> 24
- ||| E2307 / Eisai
New P1 trial: A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects (clinicaltrials.gov) - Nov 13, 2014
P1, N=64, Recruiting, Sponsor: Eisai Co., Ltd.